Scholarlink

Background <p>Oral anticoagulants (OACs) used to treat nonvalvular atrial fibrillation (NVAF) are frequently associated with complications, especially gastrointestinal hemorrhage (GH). The aim was to determine the use of resources and costs in the in-hospital treatment of GH in a group of patients with NVAF from Colombia.</p> Methods <p>This was a retrospective study of a cohort of patients who were diagnosed with NVAF and treated with an OAC (apixaban, rivaroxaban, dabigatran or warfarin) between 2018 and 2022 and who were hospitalized for GH. Information on diagnoses, GH location, administered medications, procedures, hospital stay, and health care costs was collected, adjusted to 2022.</p> Results <p>In total, 59 patients from nine different cities were identified, the mean age was 82.9 ± 12.6 years, and most were men (61.0%) who were admitted to nine clinics for GH. Upper GH was the most frequently identified form (78.0%). The most commonly used OACs were apixaban (44.1%), rivaroxaban (35.6%), warfarin (15.3%) and dabigatran (5.1%). The mean hospital stay was 6.4 ± 5.9 days, and 18.3% of the patients were admitted to the intensive care unit. Patients also received medications that increase the risk of bleeding, such as acetylsalicylic acid (45.8%), the antiplatelet inhibitor P2Y12 (15.3%) and systemic glucocorticoids (23.7%). The average direct cost of all hospital care was USD 872 ± 1315 per patient, which corresponds to 13% of the country’s gross domestic product per capita.</p> Conclusions <p>GH patients with NVAF generates a significant cost for the use of resources such as medications, procedures and care that affect the country’s health system.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Use of resources and cost in the management of gastrointestinal hemorrhage caused by oral anticoagulants: a retrospective cohort analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月24日

查看全文
  • Manuel Enrique Machado-Duque,
  • Andrés Gaviria-Mendoza,
  • Luis F. Valladales-Restrepo,
  • Diego Mauricio Gómez,
  • Alejandro Mesa-Urdinola,
  • Andrea Constanza Rubio,
  • Juan Manuel Reyes,
  • Natalia Castaño Gamboa,
  • Jorge Enrique Machado-Alba

摘要

Background

Oral anticoagulants (OACs) used to treat nonvalvular atrial fibrillation (NVAF) are frequently associated with complications, especially gastrointestinal hemorrhage (GH). The aim was to determine the use of resources and costs in the in-hospital treatment of GH in a group of patients with NVAF from Colombia.

Methods

This was a retrospective study of a cohort of patients who were diagnosed with NVAF and treated with an OAC (apixaban, rivaroxaban, dabigatran or warfarin) between 2018 and 2022 and who were hospitalized for GH. Information on diagnoses, GH location, administered medications, procedures, hospital stay, and health care costs was collected, adjusted to 2022.

Results

In total, 59 patients from nine different cities were identified, the mean age was 82.9 ± 12.6 years, and most were men (61.0%) who were admitted to nine clinics for GH. Upper GH was the most frequently identified form (78.0%). The most commonly used OACs were apixaban (44.1%), rivaroxaban (35.6%), warfarin (15.3%) and dabigatran (5.1%). The mean hospital stay was 6.4 ± 5.9 days, and 18.3% of the patients were admitted to the intensive care unit. Patients also received medications that increase the risk of bleeding, such as acetylsalicylic acid (45.8%), the antiplatelet inhibitor P2Y12 (15.3%) and systemic glucocorticoids (23.7%). The average direct cost of all hospital care was USD 872 ± 1315 per patient, which corresponds to 13% of the country’s gross domestic product per capita.

Conclusions

GH patients with NVAF generates a significant cost for the use of resources such as medications, procedures and care that affect the country’s health system.